drugset / Press release
T3D Therapeutics Chosen as Late-Breaking Addition to Alzheimer’s Association International Conference to Discuss Rapid Onset of Cognitive Improvement with T3D-959
2016-07-21 · T3D Therapeutics, Inc. · original t3dtherapeutics.com ↗
On Wednesday, July 27th in Toronto, T3D Therapeutics will present Preliminary Results of a 36-patient, two-week Phase 2a Open Label Feasibility Clinical Trial, showing Rapid Onset of Cognitive Improvements in a Subset of Mild and Moderate Alzheimer’s Patients Treated with T3D-959 Read More
The release as fetched from its publisher. t3dtherapeutics.com ↗